Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20221130056672N6
IRCT20221130056672N6
Not yet recruiting
Phase 1

Assessment of Safety and Efficacy of Intradermal Injection of Wharton's jelly Mesenchymal Cells Derived Extracellular Vesicles With CO2 Laser in Treatment of Melasma(A randomized controlled intervention study)

Tehran University of Medical Sciences0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
30
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Age between 18 and 50 years Full satisfaction of the participant in the plan Has melasma (with all three degrees of mild, moderate, severe)

Exclusion Criteria

  • •Previous treatment of melasma
  • •Pregnancy and Breastfeeding
  • •Active skin infection
  • •Use of drugs that can affect bleeding or clotting mechanism
  • •Immunosuppression
  • •Use of local and systemic steroids Disease systemic diseases (such as high blood pressure ,Diabetes ,heart, kidney and liver diseases)
  • •The use of exfoliators 4 weeks before treatment In places where botulinum injection has been done, should not be done due to the possibility of microneedle toxin release.
  • •Participation in other clinical trials

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
Investigating nanofat injection and conditioned medium derived from stem cells in the treatment of androgenic alopeciaHair loss.Nonscarring hair loss, unspecifiedL65.9
IRCT20200127046282N34Tehran University of Medical Sciences10
Not yet recruiting
Phase 1
Investigating the safety and efficacy of injection of fat tissue cells in patients with sclerodermascleroderma.Systemic sclerosis [scleroderma]
IRCT20200127046282N35Tehran University of Medical Sciences18
Not yet recruiting
Phase 2
Facial Pigmentation Treatment by Injection Tranexamic acid intradermally in skiHealth Condition 1: L811- Chloasma
CTRI/2022/02/040450Dr Meghna Khatri
Not yet recruiting
Not Applicable
Comparative study of Intradermal versus Intralesional Purified Protein Derivative (PPD) for treatment of common warts in childreHealth Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
CTRI/2019/07/020070Himachal Pradesh University
Completed
Phase 3
The saftey and efficacy of intradermal injection of type A butulinum toxin in chemotherapy induced peripheral neuropathyChemotherapy induced neuropathy.
IRCT20200425047202N1Shahid Beheshti University of Medical Sciences40